What's Happening?
Intas Pharmaceuticals, through its subsidiary Accord Plasma B.V., has signed an agreement to acquire Prothya Biosolutions Belgium BV, a leading plasma-derived medicinal products (PDMP) company. This acquisition aims to expand Intas's presence in the global PDMP market, leveraging Prothya's operations in the Netherlands and Belgium. Prothya, formed in 2021, is one of Europe's largest plasma fractionators, employing around 1,200 people. The acquisition will enhance Intas's fractionation capabilities, allowing it to serve patients worldwide with critical therapies. The deal is subject to regulatory clearances and is expected to close soon.
AD
Why It's Important?
The acquisition of Prothya Biosolutions by Intas Pharmaceuticals is significant for the global PDMP market, which is valued at $30 billion and projected to reach $50 billion by 2035. This move positions Intas to become a major player in the international plasma market, expanding its footprint beyond India. The deal will provide Intas with additional fractionation capacity and access to Prothya's established plasma collection network. This expansion is likely to benefit patients globally by increasing the availability of under-prescribed therapies, particularly intravenous immunoglobulin (IVIG).
What's Next?
Following the acquisition, Intas plans to integrate Prothya's operations with its existing plasma division in India, enhancing its global plasma platform. The company aims to increase its fractionation capacity and expand its market reach, supported by Accord's commercial presence in 85 countries. The acquisition is expected to drive further growth and innovation in the PDMP sector, with Intas focusing on strategic partnerships and R&D investments to meet diverse healthcare needs worldwide.
